Hospital finances across Illinois are getting pinched again, as rising drug and medical-supply costs eat into operating margins that had only recently started to stabilize after the pandemic shocks. Finance chiefs say non-labor expenses are climbing faster than incoming revenue, leaving less cash for routine upgrades, maintenance, and new programs. The strain is hitting systems with thin reserves hardest, along with rural hospitals that were already living on razor-thin margins.
According to Crain's Chicago Business, benchmarking data show that drug and supply spending is a key culprit behind shrinking margins at Illinois hospitals. Reporter Jon Asplund drew on monthly performance benchmarks and conversations with analysts who have been tracking the squeeze.
What the Data Show
National figures from Strata Decision Technology put numbers to the trend. Median operating margins for health systems fell to negative 0.6% in January 2026, even as patient volumes continued to look relatively solid. At the same time, drug expense per adjusted patient day climbed sharply compared with a late-2023 baseline in the fourth quarter of 2023.
Strata's chief data officer called out the warning sign directly, saying, "Margins turning negative to start the year is a clear signal that financial conditions remain fragile," and pointed to how little leverage hospitals have when drug and supply prices keep ratcheting up.
How Illinois Hospitals Stacked Up
Crain's Chicago Business reported that Illinois hospitals saw their operating margins dip in months when non-labor costs climbed the fastest. In one snapshot highlighted in the analysis, October 2025 operating margins were down 0.6% from a year earlier, even though gross margins and patient volumes were both higher.
That split, with revenue and volumes rising while operating margins still slid, underscored how quickly drug and supply spending can outpace gains on the inpatient and outpatient sides of the business.
Why Costs Keep Climbing
Executives and analysts are not pointing to a single smoking gun. Instead, they describe a pileup of pressures: more high-priced specialty biologic and oncology drugs in use, rising fees tied to infusion and pharmacy services, and lingering supply chain shifts that have driven up the price of implants and disposable items.
Industry coverage summarized by Becker's Hospital Review notes that drug expense growth has been one of the biggest forces behind recent non-labor cost increases for health systems.
What This Means for Care and Budgets
The timing is especially tricky, because federal changes to Medicaid financing are reshaping how states can backstop their hospitals. New restrictions on provider taxes and tighter limits on state-directed payments are narrowing the budget tools that governors and legislatures can use to support hospital reimbursement.
The National Association of Counties has laid out how the reconciliation law's rules on provider taxes and state-directed payments reduce that flexibility, a shift that could pose a particular challenge for safety-net hospitals in Illinois that rely heavily on Medicaid dollars.
Bottom Line
For hospital leaders in Chicago and across the state, the immediate playbook is not especially glamorous: trim other nonclinical spending, try to negotiate higher rates from insurers, or slow down capital projects and building plans.
Yet as Strata Decision Technology points out, those tactics might soften the financial hit but will not, on their own, reverse the larger upward trend in drug and supply costs without broader changes in the market or in policy.
